ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Get Free Report) Director Laura Shawver sold 50,002 shares of ARS Pharmaceuticals stock in a transaction that occurred on Monday, April 7th. The stock was sold at an average price of $12.30, for a total value of $615,024.60. Following the sale, the director now directly owns 210,346 shares of the company's stock, valued at approximately $2,587,255.80. The trade was a 19.21 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Laura Shawver also recently made the following trade(s):
- On Thursday, March 6th, Laura Shawver sold 49,600 shares of ARS Pharmaceuticals stock. The stock was sold at an average price of $11.21, for a total value of $556,016.00.
- On Monday, February 3rd, Laura Shawver sold 50,000 shares of ARS Pharmaceuticals stock. The shares were sold at an average price of $12.31, for a total transaction of $615,500.00.
ARS Pharmaceuticals Trading Down 3.9 %
Shares of NASDAQ SPRY opened at $12.33 on Wednesday. The company has a market cap of $1.21 billion, a price-to-earnings ratio of -24.18 and a beta of 0.86. ARS Pharmaceuticals, Inc. has a 12 month low of $7.55 and a 12 month high of $18.51. The stock has a 50-day moving average price of $11.96 and a two-hundred day moving average price of $13.04.
ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last issued its quarterly earnings data on Thursday, March 20th. The company reported $0.52 EPS for the quarter, beating the consensus estimate of ($0.04) by $0.56. The company had revenue of $86.58 million during the quarter, compared to the consensus estimate of $15.46 million. On average, sell-side analysts predict that ARS Pharmaceuticals, Inc. will post -0.55 earnings per share for the current year.
Analyst Ratings Changes
A number of research analysts have issued reports on the stock. Raymond James increased their target price on shares of ARS Pharmaceuticals from $26.00 to $28.00 and gave the stock a "strong-buy" rating in a research report on Tuesday, January 14th. Leerink Partners increased their price target on ARS Pharmaceuticals from $26.00 to $27.00 and gave the stock an "outperform" rating in a research report on Monday, January 13th. Oppenheimer initiated coverage on ARS Pharmaceuticals in a report on Monday, February 10th. They issued an "outperform" rating and a $40.00 price objective for the company. William Blair reissued an "outperform" rating on shares of ARS Pharmaceuticals in a report on Monday, March 3rd. Finally, Scotiabank began coverage on ARS Pharmaceuticals in a research note on Friday, March 7th. They issued a "sector outperform" rating and a $30.00 price target for the company. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Buy" and an average price target of $31.00.
Get Our Latest Stock Report on ARS Pharmaceuticals
Institutional Investors Weigh In On ARS Pharmaceuticals
Hedge funds have recently modified their holdings of the company. Charles Schwab Investment Management Inc. grew its holdings in shares of ARS Pharmaceuticals by 2.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 423,947 shares of the company's stock worth $6,147,000 after purchasing an additional 8,417 shares during the last quarter. The Manufacturers Life Insurance Company increased its position in ARS Pharmaceuticals by 121.1% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 46,854 shares of the company's stock valued at $679,000 after acquiring an additional 25,658 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of ARS Pharmaceuticals by 766.1% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 234,537 shares of the company's stock valued at $3,401,000 after acquiring an additional 207,456 shares during the last quarter. HighTower Advisors LLC lifted its holdings in shares of ARS Pharmaceuticals by 18.2% during the third quarter. HighTower Advisors LLC now owns 28,310 shares of the company's stock worth $411,000 after purchasing an additional 4,369 shares during the period. Finally, Stifel Financial Corp bought a new stake in shares of ARS Pharmaceuticals in the third quarter worth $199,000. Institutional investors and hedge funds own 68.16% of the company's stock.
ARS Pharmaceuticals Company Profile
(
Get Free Report)
ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
